Physician profile
Shane Clark
NPI 1548495336
$4,361.34
in general payments reported to CMS, 2019-2025
22 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $364 · 2021: $113 · 2022: $689 · 2023: $459 · 2024: $664 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.48 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $834.56 | 2019-2025 | Tremfya |
| Abbvie INC. | $816.67 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $344.31 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $322.83 | 2019-2025 | Ebglyss |
| Dermavant Sciences, INC. | $319.64 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $235.03 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $233.49 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $175.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.16 | 2022-2023 | Spevigo |
| Galderma Laboratories, L.P. | $138.05 | 2023-2025 | Nemluvio, Epsolay, Aklief |
| Ucb, INC. | $126.10 | 2024-2025 | Bimzelx |
| Amgen INC. | $124.49 | 2019-2024 | Otezla |
| Genzyme Corporation | $124.08 | 2021-2025 | |
| Organon LLC | $91.19 | 2025 | Vtama, Nexplanon |
| Incyte Corporation | $87.76 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44.14 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.49 | 2024 | Jublia, Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $42.95 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $39.79 | 2022-2025 | |
| Celgene Corporation | $22.69 | 2019 | |
| Pfizer INC. | $16.99 | 2022 | |
| Epi Health, LLC | $4.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.